Loading...

NKT cell adjuvants in therapeutic vaccines against hematological cancers

Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent s...

Full description

Saved in:
Bibliographic Details
Main Authors: Mattarollo, Stephen R., Smyth, Mark J.
Format: Artigo
Language:Inglês
Published: Landes Bioscience 2013
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3583928/
https://ncbi.nlm.nih.gov/pubmed/23482240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.22615
Tags: Add Tag
No Tags, Be the first to tag this record!